Author: Andrei Bilog M.Sc., CAPM

Over the past two years, layoffs across the biotech and pharmaceutical sectors have continued to make headlines. For students pursuing careers in healthcare or biotechnology—and even professionals already working in the industry—this can feel unsettling.

You might be wondering: Is biotech still a stable career?

The short answer is yes—but the industry operates in cycles. Understanding those cycles can help you navigate your career more strategically.

Biotech layoffs are not isolated events—they’re part of a broader restructuring cycle across the life sciences sector.

In 2025, layoffs across biopharma companies increased 16% year over year, reflecting continued restructuring after the pandemic-era surge in biotech investment (Masson, 2026).

Meanwhile, several pharmaceutical and biotech companies announced workforce reductions in early 2026 as organizations refocused pipelines, cut costs, and prioritized high-probability drug programs.

Even in major biotech hubs, the impact has been significant. Thousands of life sciences workers were laid off in the past year as companies scaled back research programs and reallocated funding.

Several structural factors are driving this trend:

These forces are not new. The biotechnology industry has historically expanded during periods of strong investment and contracted when capital becomes more selective.

Research shows that employment in biotechnology is strongly linked to research and development investment cycles, which directly influence hiring and layoffs across the sector (Pisano, 2006).

Even though I personally haven’t experienced being laid off, I’ve seen how quickly things can change.

In July 2025, I was on vacation in Japan when about 20% of employees in my department were laid off.

I remember getting the news while I was away, and it was honestly shocking.

When I came back from vacation, the atmosphere at work felt completely different. People who had been there for years were suddenly gone. Projects shifted. Teams were reorganized.

And there was a strange emotional layer to it.

Earlier that same year, in January 2025, I had received a promotion. Instead of just feeling grateful, I also felt a sense of guilt. Why did I stay while others were let go?

That’s something people don’t talk about enough in layoffs—the survivor’s guilt that can follow.

Even months later, there were lingering effects.

When layoffs happen, uncertainty spreads through the organization. People start wondering:

And subconsciously, many employees start pushing themselves harder—taking on more work, staying later, volunteering for projects—because no one wants to be seen as expendable.

That psychological pressure is real, and it’s something many professionals experience during industry downturns.

Research on workplace restructuring shows that employees who remain after layoffs often experience increased stress, job insecurity, and productivity pressure, a phenomenon sometimes referred to as “layoff survivor syndrome” (Noer, 2009).

The biotech industry is inherently high-risk.

Developing a new drug can take 10–15 years and billions of dollars, with most drug candidates failing before reaching the market (DiMasi et al., 2016).

Because of this, biotech companies constantly make difficult decisions about where to allocate resources.

If a clinical program fails, an entire research division might shut down overnight.

If funding dries up, startups may have to cut staff just to survive long enough to reach their next milestone.

From the outside, layoffs can look chaotic. But internally, they are often tied to strategic decisions about which therapies have the highest probability of success.

If you’re studying biology, biotechnology, or entering healthcare careers, layoffs should not discourage you.

Instead, they should motivate you to build career resilience.

Here are three things I consistently tell my students:

Learn tools and knowledge that apply across industries—data analysis, regulatory science, biostatistics, manufacturing operations, and communication.

Scientific breakthroughs matter, but funding decisions determine which projects move forward.

Understanding biotech strategy, venture funding, and clinical pipelines can make you far more valuable.

Networking is one of the most powerful career tools in biotech.

Mentorship, internships, and professional connections often determine who hears about opportunities first.

Programs that help scientists build professional networks and industry exposure have been shown to significantly improve career mobility in bioscience fields (Lakofsky, 2023).

Layoffs are difficult, but they don’t define the future of biotechnology.

The demand for new therapies continues to grow as populations age and diseases become more complex.

Breakthroughs in gene therapy, AI-driven drug discovery, and personalized medicine are already reshaping the healthcare landscape.

Biotech will continue to evolve—but the scientists, engineers, clinicians, and professionals who adapt will always be needed.

If you’re a student or early-career professional reading this, remember:

Your career in science is not defined by a single company, a single project, or even a single industry cycle.

It’s defined by your ability to learn, adapt, and keep moving forward.

And in biotech, that mindset is everything. 🧬

DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33.

Lakofsky, K. (2023). Bridging the talent gap: Connecting talent to bioscience careers. Journal of STEM Workforce Development. https://pmc.ncbi.nlm.nih.gov/articles/PMC10759971/

Noer, D. M. (2009). Healing the wounds: Overcoming the trauma of layoffs and revitalizing downsized organizations. Jossey-Bass.

Pisano, G. P. (2006). Science business: The promise, the reality, and the future of biotech. Harvard Business School Press.

Masson, G. (2026). Layoff rounds rise 16% year over year in biopharma. Fierce Biotech.

Disclaimer: This article was assisted by AI-based language tools (ChatGPT, OpenAI) for drafting and organization. All content was reviewed by the author, and all claims are supported by peer-reviewed sources.